The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Duration of targeted therapy in metastatic renal cell carcinoma patients with ECOG PS>2.
Ilya Tsimafeyeu
No relevant relationships to disclose
Natalia N. Petenko
No relevant relationships to disclose
Anton Snegovoy
No relevant relationships to disclose
Sergey Varlamov
No relevant relationships to disclose
Lev V. Demidov
No relevant relationships to disclose